[Retracted] Circ TYMP1 Inhibits Carcinogenesis and Cisplatin Resistance in Ovarian Cancer by Reducing Smad2/3 Phosphorylation via a MicroRNA‐182A‐3p/TGF1B Axis
TYMP1 is a cancer driver in several human malignancies. However, its significance in ovarian cancer (ovarian carcinoma) remains uncertain. This research aims to understand the TYMP1’s role in ovarian carcinoma carcinogenesis and cisplatin (DDP) resistance and its molecular ovarian marchionesses. Circ TYMP1 overexpression in ovarian carcinoma samples led to an accelerated tumor stage. Bioinformatics identified miR‐182A‐3p as the TYMP1’s target transcript. Circ TYMP1 functioned as a sponge for miR‐182A‐3p, lowering its inhibitory effect on TGF1B. Downregulating circ TYMP1 decreased A2780‐Res cell proliferation, invasion, and death resistance. Malignant ovarian carcinoma cells recovered following miR‐182A‐3p downregulation. TGF1B overexpression boosted A2780‐Res cell proliferation, aggression, and cisplatin resistance while reducing Smad2/3 phosphorylation. TYMP1 sequesters miR‐182A‐3p and promotes TGF1B in ovarian carcinoma, boosting carcinogenesis and cisplatin resistance. This might lead to novel ovarian carcinoma treatments.
